TABLE 1.
Demographics, APOE, and Copathologies of Included Subjects (n = 383)
| LATE-NC-* | LATE-NC+* | p-value** | |
|---|---|---|---|
| N | 262 | 121 | |
| Age of death, average (Avg) | 87.8 | 89.4 | 0.014 |
| Sex, %F | 61.5 | 61.1 | 0.96 |
| MMSE, Avg | 24.0 | 17.7 | 6.4 E-13 |
| APOE 4+ (%) | 34.7 | 38.8 | 0.44 |
| Brain weight (g), Avg | 1174.5 | 1119.2 | 0.001 |
| Cortical Lewy body pathology (%) | 8.8 | 11.6 | 0.39 |
| Arteriolosclerosis (0–3), Avg | 1.08 | 1.23 | 0.13 |
| Cerebral amyloid angiopathy (0–3), Avg | 0.73 | 1.08 | 0.002 |
| Gross infarcts, Avg | 0.54 | 0.50 | 0.79 |
| Braak NFT stage, Avg | 3.35 | 4.32 | n/a |
| CERAD neuritic plaque density (0–3), Avg | 1.47 | 2.05 | n/a |
| Hippocampal sclerosis (%) | 5.3 | 68.6 | 1.7 E-52 |
*
Limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes (LATE-NC) indicates LATE-NC Stage >1.
**
Comparing LATE-NC- versus LATE-NC+; Student t-test, 2-tailed.